TechnoVax is a biotechnology company specializing in viral vaccine development. It utilizes a technology platform based on virus-like particles (VLP) to produce vaccines targeting the prevention of respiratory diseases as well as haemorrhagic fevers, immunodeficiency, and cancers. The company develops vaccine candidates, including a broadly neutralizing influenza vaccine, a non-refrigerated inhaled powder influenza vaccine, and a VLP-based respiratory syncytial virus vaccine.